Rubicyt 50mg Injection
Prescription Required
Product introduction
Rubicyt 50mg Injection is used in the treatment of various types of cancers of blood, breast, stomach, lung, ovaries and soft tissues. It also helps to prevent the recurrence of bladder cancer after surgery.
Rubicyt 50mg Injection is used to treat a variety of cancers, either alone or in combination with other drugs.
Rubicyt 50mg Injection is used to treat a variety of cancers, either alone or in combination with other drugs.
Uses of Rubicyt Injection
Benefits of Rubicyt Injection
In Cancer
Rubicyt 50mg Injection helps to treat certain kinds of cancer. It may be used alone or in combination with other medicines to treat cancer in various parts of the body. Rubicyt 50mg Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Side effects of Rubicyt Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Rubicyt
- Low blood platelets
- Nausea
- Hair loss
- Absence of menstrual periods
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Weight loss
- Decreased white blood cell count (neutrophils)
- Hot flashes
- Gastrointestinal inflammation
- Rash
- Low energy
- Eye disorder
How to use Rubicyt Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Safety advice
Alcohol
UNSAFE
It is unsafe to consume alcohol with Rubicyt 50mg Injection.
Pregnancy
CONSULT YOUR DOCTOR
Rubicyt 50mg Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding
UNSAFE
Rubicyt 50mg Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving
UNSAFE
Rubicyt 50mg Injection may cause side effects which could affect your ability to drive.
Rubicyt 50mg Injection may cause episodes of nausea and vomiting, which can temporarily lead to an impairment of the ability to drive.
Rubicyt 50mg Injection may cause episodes of nausea and vomiting, which can temporarily lead to an impairment of the ability to drive.
Kidney
SAFE IF PRESCRIBED
Rubicyt 50mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Rubicyt 50mg Injection may not be needed in these patients. Please consult your doctor.
Lower doses may be considered in patients with serum creatinine > 5 mg/dL.
Lower doses may be considered in patients with serum creatinine > 5 mg/dL.
Liver
CAUTION
Rubicyt 50mg Injection should be used with caution in patients with liver disease. Dose adjustment of Rubicyt 50mg Injection may be needed. Please consult your doctor.
Use of Rubicyt 50mg Injection is not recommended in patients with severe liver disease.
Use of Rubicyt 50mg Injection is not recommended in patients with severe liver disease.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Rubicyt 50mg Injection
₹2078.96/Injection
Zuvicin 50mg Injection
Zuventus Healthcare Ltd
₹1298/injection
38% cheaper
Epicure 50mg Injection
Emcure Pharmaceuticals Ltd
₹1113/injection
46% cheaper
Epithra 50mg Injection
Glenmark Pharmaceuticals Ltd
₹1060/injection
49% cheaper
Farmorubicin RD 50mg Injection
Pfizer Ltd
₹3168/injection
52% costlier
Erubin 50mg Injection
RPG Life Sciences Ltd
₹597/injection
71% cheaper
Quick tips
- Rubicyt 50mg Injection is used alone or in combination with other medicines for the treatment of various types of cancers.
- It is given through a drip into a vein (intravenous infusion) by a doctor or nurse.
- It may make you feel tired or sleepy. Do not drive or do anything that requires mental focus until you know how it affects you.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for 6 months after stopping treatment.
- Your doctor may get regular blood tests done to monitor your blood cells, liver, and heart function during treatment with this medicine.
- Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
Fact Box
Chemical Class
Anthracycline Derivative
Habit Forming
No
Therapeutic Class
ANTI NEOPLASTICS
Action Class
Alkaloids-cytotoxic agents
Patient concerns
FAQs
Is Rubicyt 50mg Injection a vesicant (agent that causes tissue blistering and damage)?
Yes, Rubicyt 50mg Injection is a vesicant; it may cause tissue blistering if it leaks out of the vein.
How effective is Rubicyt 50mg Injection?
Rubicyt 50mg Injection is effective in the treatment of various cancers including cancer of the breast, ovary, stomach, lung, bowel or rectum, malignant lymphomas (a type of blood cancer of infection-fighting cells of the blood) such as Hodgkin's disease and non-Hodgkin's lymphoma, leukemia (blood cancer), multiple myeloma (a type of blood cancer of infection-fighting cells of the blood). It may be used in bladder cancers and to prevent reoccurrence of bladder cancer after surgery. It effectively slows or stops the growth of cancer cells in the body.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 1715.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 952.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 478-79.
- Epirubicin hydrochloride. Wedel, Germany: Medac GmbH; 2008 [revised Jun. 2016]. [Accessed 26 Mar. 2019] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
Marketer details
Name: Cytogen Pharmaceuticals India Pvt Ltd
Address: Cytogen Pharmaceuticals India Pvt. Ltd., 105, Anupam Plaza, 6, Local shopping Complex Gazipur, Delhi-96.
Country of origin: India
Lab tests offered by us
Related/Popular tests
MRP
₹2078.96
Inclusive of all taxes
1.0 Injection in 1 vial
SOLD OUT